Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance

In this pilot clinical trial, we evaluated rates of residual replication in persons without lamivudine resistance-associated mutations in proviral DNA population sequencing who switched to dolutegravir plus lamivudine. After 144 weeks, there was no signal of changes in residual viremia based on qual...

Descripción completa

Detalles Bibliográficos
Autores principales: De Miguel Buckley, Rosa, Rial-Crestelo, David, Montejano, Rocío, Pinto, Adriana, Jimenez-Gonzalez, María, Lagarde, Maria, Esteban-Cantos, Andrés, Aranguren-Rivas, Paula, Cadiñanos, Julen, Bisbal, Otilia, Castro, Juan Miguel, Santacreu-Guerrero, Mireia, Bermejo-Plaza, Laura, Moreno, Victoria, Hernando, Asunción, Martín-Carbonero, Luz, Rubio, Rafael, Delgado, Rafael, Arribas, José Ramón, Pulido, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697602/
https://www.ncbi.nlm.nih.gov/pubmed/36447613
http://dx.doi.org/10.1093/ofid/ofac610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697602/
https://www.ncbi.nlm.nih.gov/pubmed/36447613
http://dx.doi.org/10.1093/ofid/ofac610

Ejemplares similares